Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott sales

This article was originally published in The Tan Sheet

Executive Summary

Worldwide sales of nutritional products during the fourth quarter were fueled by the performance of the international division, which posted sales growth of 26.2% to $571 mil., Abbott Labs says in Jan. 23 release. International growth was driven by a 6.6% favorable impact from exchange, "with continued strong growth in Latin American and Asian markets," firm says. Total sales of the division increased 11.2% to $1.19 bil. Revenues for U.S. nutritional products were flat at $616 mil., however, excluding the impact of a co-promotion agreement for Rx drug Synagis, U.S. sales of the unit advanced 11%, Abbott notes. For the year, Abbott's international nutritional products division had sales growth of 18.4% to $2.04 bil., boosting net sales for nutritionals 1.7% to $4.39 bil. U.S. nutritional revenues fell 9.4% to $2.35 bil., reflecting the impact of Synagis...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS101286

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel